SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The stock is trending due to heightened speculation around impending Phase 3 results for its lead AML immunotherapy, GPS, with the CEO's recent remarks on "curative outcomes" fueling strong community belief in a positive data readout and potential buyout. This has intensified discussions of a significant short squeeze as institutional accumulation is noted and the stock approaches new highs.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

ANTX is trending due to a cluster of recent positive developments including a $40 million private placement, new strategic partnerships with GSK and DNDi, and an analyst upgrade, sparking intense community debate between aggressive bulls targeting significant price appreciation and bears pointing to past trial setbacks and potential dilution.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending amid intense community speculation of an impending short squeeze, driven by perceived technical breakouts and widespread anticipation of strategic announcements or positive earnings from Chairman Ryan Cohen, with many noting its resilience in a volatile market.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is trending following positive 12-month Phase 2 trial data for its bladder cancer candidate, NDV-01, which reported a durable 76% complete response rate and reinforced plans for Phase 3 trials. The company's recently announced $160 million private placement to fund further development is also a key talking point, with the community actively discussing the drug's potential and the financing's implications for its future trajectory.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

Aureus Greenway Holdings is trending due to its announced merger with drone manufacturer Powerus, backed by Eric and Donald Trump Jr., signaling a significant pivot into the defense-drone sector amid rising military tech demand. Community discussion reflects strong enthusiasm for potential government contracts and short squeeze opportunities, while also acknowledging concerns around the stated merger valuation and recent share dilution.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending after resolving its legal dispute with Novo Nordisk and announcing a partnership to offer FDA-approved GLP-1 weight-loss medications on its platform. This development has largely eliminated the previous bear thesis, fueling significant short-squeeze speculation and community discussion about the company's long-term potential as a digital health and wellness platform.

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Calamp Corp.

Calamp Corp. is currently trending due to its Chapter 11 bankruptcy filing and plan to go private, which is expected to eliminate existing shareholder equity. Investors are actively discussing the impending delisting and the ultimate value of their holdings.

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Solid Biosciences is trending following an oversubscribed $240 million private placement bolstering its cash runway and recent positive regulatory updates across its Duchenne, Friedreich's Ataxia, and cardiac gene therapy programs, igniting strong institutional interest and short-squeeze speculation among the community.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co. trends amid the upcoming CEO transition to Josh D'Amaro on March 18 and the successful debut of Pixar's 'Hoppers,' fueling community discussion over whether these catalysts, alongside a new stock buyback, can address ongoing concerns about content performance and valuation.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending on a wave of multiple analyst price target upgrades and its Revuforj drug being recognized as "Best New Drug" at the Scrip Awards. The community is actively discussing strong revenue growth, perceived undervaluation against peers, and high anticipation for a potential buyout, especially by Incyte, alongside upcoming positive data from major conference presentations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cameco's Valuation Looks Pricey: Buy, Hold or Sell the Stock?

CCJ's long-term uranium contracts and rising nuclear demand support its outlook, but premium valuation and softer 2026 revenue guidance may temper enthusiasm.

Is Centrus Energy Stock Worth Buying After Recent Drop?

LEU stock drops more than 20% recently, but premium valuation, strong liquidity and modest growth forecasts keep the outlook balanced.

Centrus Energy Positioned for Growth as HALEU Demand Accelerates

LEU expands U.S. enrichment capacity and strengthens HALEU leadership as a $3.8B backlog and rising advanced reactor fuel demand shape its growth outlook.

UEC Gears Up to Report Q2 Earnings: What's in Store for the Stock?

Uranium Energy heads into Q2 fiscal 2026 earnings with a wider loss expected as higher exploration and development spending offsets uranium price gains.

Cameco Inks $1.9B Long-Term Uranium Supply Deal With India

CCJ seals a CAD 2.6B uranium supply pact with India through 2036, locking in 22M pounds as nuclear expansion accelerates.

Uranium Energy Corp Provides Date for Fiscal 2026 Second Quarter Results, Conference Call, and Webcast

Uranium Energy Corp Provides Date for Fiscal 2026 Second Quarter Results, Conference Call, and Webcast Uranium Energy Corp Provides Date for Fiscal 2026 Second Quarter Results, Conference Call, and...

Energy Fuels vs. Uranium Energy: Which Uranium Stock Has an Edge?

UUUU stands out in the uranium race with strong production growth, new supply deals and rare earth expansion, outpacing UEC on revenue outlook and valuation.

Is It Worth Investing in Uranium Energy (UEC) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Uranium Energy (UEC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

UUUU Surges 134% in Past Six Months: How to Play the Stock?

Energy Fuels surges 134% in six months on rare earth expansion and uranium strength, but losses, valuation and downward revisions raise caution.

Should You Buy, Sell or Hold CCJ Stock Before Q4 Earnings Release?

Cameco gears up for Q4 results with steady output, firmer uranium prices and Westinghouse gains. Can it deliver an earnings beat?

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

UEC
Uranium Energy Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest UEC News

UECUranium Energy Corp